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medical resource use and total costs, after adjustment for
baseline characteristics. Such observations are of rele-
vance in the interpretation of economic evaluation results,
and should be assessed in different disease areas.
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OBJECTIVE: An international phase III trial (PROWESS,
N = 1690) assessed that treatment with drotrecogin alfa
(activated) reduced 28-day mortality among patients with
severe sepsis. In the present study, cost effectiveness
analyses are performed of this therapy in the treatment
of severe sepsis (SS) and severe sepsis with multiple organ
failure (SS/MOF) in Italy. METHODS: A decision model
was developed based on PROWESS outcomes and
resource use information. Absolute reduction in hospital
mortality at day 28 was 6.0% (7.3% for patients with 2
or more organ dysfunctions at baseline (N = 1271)). Italy-
speciﬁc cost data were applied to the resource use pat-
terns of the European trial patients. Hospitalisation costs
were based on published full daily cost estimates for ICU
(€1,033) and the regular ward (€300). Assumed drotre-
cogin alfa (activated) cost in Italy is €261 per 5mg vial,
including VAT. Placebo arm cost of standard care includes
€1,580 for Anti-thrombin III (ATIII) which is often used
for treatment of sepsis patients in Italy but which has not
shown a reduction in mortality in major trials (7,392U
ATIII per patient at €381 per 1,000U (for 56% patients
(from an expert panel)). Italian Life Tables were used to
estimate life expectancy; which was adjusted for effects
of severe sepsis. RESULTS: The estimated incremental
cost per life year gained for drotrecogin alfa (activated)
is €13,436 for SS (€17,148 discounting life years at 3%)
and for SS/MOF is €9,660 (€12,284). CONCLUSIONS:
A rule-of-thumb maximum acceptable value for a life year
gained is about €50,000. Another suggested standard, the
per capita GDP, would be about €20,000 for Italy. Both
such amounts by far exceed the amount here reported for
drotrecogin alfa (activated), which appears to be cost
effective for the treatment of patients with severe sepsis,
and severe sepsis with multiple organ failure, in Italy.
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OBJECTIVES: In the PROWESS trial (n = 1690),
drotrecogin alfa (activated) (recombinant human Acti-
vated Protein C) signiﬁcantly decreased the 28-day mor-
tality in adults with severe sepsis compared with placebo
(ARR 6,1%; p = 0,005). A cost-effectiveness analytical
model was conducted to assess the efﬁciency of the drug
in Spain in the trial population and in the expected
approved indication (patients with multiple organ fail-
ures). METHODS: National Health Service perspective
was used in the analysis. Effectiveness and resource use
were obtained from data collected prospectively in the
trial. Spanish costs data of patients treated in intensive
care were applied. Direct costs assessed were drug 
cost, costs up to 28 days, and to ﬁnal discharge. Life
expectancy was estimated using actual age and sex, and
Spanish life tables, and an adjustment for post discharge
mortality associated with severe sepsis. Cost per hospital
survivor and incremental hospital cost per life year gained
(LYG) were calculated. LYG were not discounted in the
base case analysis. Sensitivity analysis was applied adjust-
ing for patterns of care, ICU costs, comorbidity and dis-
count rate. RESULTS: In patients with multiple organ
failure, drotrecogin alfa (activated) saved 7.3 additional
lives in hospital per 100 treated patients at 28 days when
compared with placebo (p < 0,05) (NNT = 14). The cost
per hospital survivor was €119,857. Hospital survivors
were estimated to live 12.2 years. The cost-effectiveness
of drotrecogin alfa (activated) was €9,799 per LYG when
compared with placebo (€13,594 per LYG for the trial
population). The sensitivity analysis indicated that the
largest inﬂuence on costs were the assumptions of the dis-
count and reduction in life expectancy of patients. CON-
CLUSIONS: In Spain, drotrecogin alfa (activated) has
shown to be efﬁcient in the treatment of severe sepsis. The
incremental CE is better than many well-accepted and
common healthcare interventions.
